Pulse Biosciences CS (PLSE) Stock Price, Quote & News

Company Profile

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment c...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 510 906 4600

Website: www.pulsebiosciences.com

Address:

601 Brickell Key Drive, Suite 1080, Miami, United States

LeisureSuitLarry May. 13 at 2:38 AM

$PLSE

0 · Reply

topstockalerts May. 12 at 9:31 PM

$PLSE wait… when did this get so strong?

0 · Reply

zzzdoc01 May. 12 at 8:10 PM

$PLSE obviously the market could care less what you think🤡🤣

0 · Reply

TruthBroker2 May. 12 at 7:27 PM

$PLSE Haters make us Greater. 🤣

0 · Reply

Orbit100 May. 12 at 7:26 PM

$PLSE Abbott CEO purchased shares at $108 for over a million dollars and its CFO purchased nearly 2 million dollars worth of stock at low $91 yet the stock continuoulsy to fall. Don't fall for the shares purchase by CEO at Pulse could make the stock goes up while ABT, BSX, MDT and JNJ failed to catch any breath to go up through large shares purchases of CEO and CFO.

1 · Reply

Orbit100 May. 12 at 7:23 PM

$PLSE While Medtronic, Boston Scientific, Abbott and Johnson Johnson has fallen so far this year, it now makes PLSE over valued as a sell.

0 · Reply

Realtrader77 May. 12 at 6:56 PM

$PLSE buyout soon.

0 · Reply

Orbit100 May. 12 at 5:53 PM

$PLSE CFRA Reiterated since 05/09/2026 Sell CFRA Quantitative Report Latest Report 05/09/2026 Argus No rating provided by Argus Market Edge Reiterated since 05/04/2026 Avoid

0 · Reply

TruthBroker2 May. 12 at 5:32 PM

$SMMT $PLSE They Know.

0 · Reply

TruthBroker2 May. 12 at 2:42 PM

$PLSE Team Pulse

0 · Reply

Pulse Biosciences announces ATM equity purchases by co-chairmen

May 12, 2026, 7:00 AM EDT - 1 day ago

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

May 8, 2026, 7:00 AM EDT - 5 days ago

Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

May 7, 2026, 4:30 PM EDT - 5 days ago

Pulse Biosciences Earnings Call Transcript: Q1 2026

2026-05-04T11:10:11.000Z - 9 days ago

Pulse Biosciences reports Q1 EPS (27c) vs (25c) last year

May 4, 2026, 7:00 AM EDT - 9 days ago

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

2026-04-26T17:40:28.000Z - 16 days ago

Pulse Biosciences presents clinical data from nPulse Cardiac Catheter System

Apr 25, 2026, 1:00 PM EDT - 17 days ago

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

2026-04-20T12:09:41.000Z - 23 days ago

Pulse Biosciences to feature nPulse tech at Heart Rhythm Society meeting

Apr 20, 2026, 7:00 AM EDT - 23 days ago

Pulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting

Apr 17, 2026, 7:00 AM EDT - 26 days ago

Pulse Biosciences to Host Analyst Event on April 25, 2026

Apr 16, 2026, 9:30 AM EDT - 26 days ago

Pulse Biosciences Transcript: 25th Annual Needham Virtual Healthcare Conference

2026-04-09T11:44:40.000Z - 4 weeks ago

Pulse Biosciences appoints Teplitsky as Chief Operating Officer

Apr 9, 2026, 7:00 AM EDT - 4 weeks ago

Pulse Biosciences Strengthens Executive Leadership Team

2026-04-07T11:27:19.000Z - 5 weeks ago

Pulse Biosciences enrolls first patients in NANOPULSE-AF study

Apr 7, 2026, 7:00 AM EDT - 5 weeks ago

Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation

Apr 2, 2026, 4:05 PM EDT - 5 weeks ago

Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference

Mar 18, 2026, 10:40 AM EDT - 7 weeks ago

Pulse Biosciences Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference

2026-03-17T11:21:11.000Z - 2 months ago

Pulse to accelerate development of nPulse Cardiac Catheter Ablarton System

Mar 17, 2026, 7:00 AM EDT - 2 months ago

Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data

Mar 12, 2026, 7:00 AM EDT - 2 months ago

Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology

2026-03-09T11:10:46.000Z - 2 months ago

Pulse Biosciences announces data from nPulse Vybrance study

Mar 9, 2026, 7:00 AM EDT - 2 months ago

Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation

Mar 5, 2026, 7:00 AM EST - 2 months ago

Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference

Mar 4, 2026, 1:10 PM EST - 2 months ago

Pulse Biosciences Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 7:00 AM EST - 2 months ago

Pulse Biosciences' nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting

Feb 20, 2026, 4:05 PM EST - 2 months ago

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-02-20T13:10:48.000Z - 2 months ago

Pulse Biosciences price target raised to $30 from $22 at Oppenheimer

Feb 20, 2026, 7:00 AM EST - 2 months ago

Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference

Feb 19, 2026, 4:30 PM EST - 2 months ago

Pulse Biosciences Earnings Call Transcript: Q4 2025

Feb 19, 2026, 4:05 PM EST - 2 months ago

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

2026-02-06T12:41:58.000Z - 3 months ago

Pulse Biosciences price target raised to $30 from $25 at Mizuho

2026-02-06T00:10:32.000Z - 3 months ago

Pulse Biosciences says nPulse study demonstrates successful treatment

Feb 5, 2026, 7:00 PM EST - 3 months ago

Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

Feb 4, 2026, 4:05 PM EST - 3 months ago

Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026

Feb 3, 2026, 7:00 AM EST - 3 months ago

Pulse Biosciences' nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium

2026-01-30T10:15:20.000Z - 3 months ago

Pulse Biosciences initiated with an Outperform at Mizuho

Jan 14, 2026, 6:45 PM EST - 4 months ago

Pulse Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 7:00 AM EST - 4 months ago

Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

Jan 6, 2026, 7:00 AM EST - 4 months ago

Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium

Dec 29, 2025, 4:05 PM EST - 4 months ago

Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-18T12:05:34.000Z - 5 months ago

Pulse Biosciences announces FDA approval of nPulse IDE

Dec 18, 2025, 7:00 AM EST - 5 months ago

Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

2025-12-09T12:16:21.000Z - 5 months ago

Pulse Biosciences initiates research collaboration for thyroid cancers treatment

Dec 9, 2025, 7:00 AM EST - 5 months ago

Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology

Dec 3, 2025, 9:50 AM EST - 5 months ago

Pulse Biosciences Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 2:40 PM EST - 6 months ago

Pulse Biosciences Transcript: Stifel 2025 Healthcare Conference

2025-11-11T20:50:24.000Z - 6 months ago

Pulse Biosciences management to meet virtually with Oppenheimer

Nov 6, 2025, 4:05 PM EST - 6 months ago

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

Nov 5, 2025, 4:30 PM EST - 6 months ago

Pulse Biosciences Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:05 PM EST - 6 months ago

Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results

2025-10-24T11:37:00.000Z - 7 months ago

Pulse Biosciences enrolls first patient in NANOCLAMP AF study

Oct 24, 2025, 7:00 AM EDT - 7 months ago

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

Oct 22, 2025, 4:05 PM EDT - 7 months ago

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

Oct 10, 2025, 7:00 AM EDT - 7 months ago

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Oct 7, 2025, 7:00 AM EDT - 7 months ago

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Sep 10, 2025, 7:00 AM EDT - 8 months ago

Pulse Biosciences' nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting

2025-09-08T11:05:07.000Z - 8 months ago

Pulse Biosciences granted FDA approval for investigational device exemption

Sep 8, 2025, 7:00 AM EDT - 8 months ago

Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation

2025-09-02T11:05:30.000Z - 9 months ago

Pulse Biosciences announces first procedures in benign thyroid nodules study

Sep 2, 2025, 7:00 AM EDT - 9 months ago

Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

2025-08-26T11:05:25.000Z - 9 months ago

Pulse Biosciences publishes benign thyroid nodules data in Journal Thyroid

Aug 26, 2025, 7:00 AM EDT - 9 months ago

Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid

Aug 13, 2025, 11:00 AM EDT - 9 months ago

Pulse Biosciences Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 4:30 PM EDT - 9 months ago

Pulse Biosciences Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:05 PM EDT - 9 months ago

Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results

Aug 1, 2025, 7:00 AM EDT - 10 months ago

Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference

Jul 29, 2025, 4:05 PM EDT - 10 months ago

Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025

2025-07-07T11:50:30.000Z - 11 months ago

Pulse Biosciences initiated with an Outperform at Oppenheimer

May 8, 2025, 4:30 PM EDT - 1 year ago

Pulse Biosciences Earnings Call Transcript: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

May 6, 2025, 4:05 PM EDT - 1 year ago

Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference

May 1, 2025, 7:00 AM EDT - 1 year ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting

Apr 24, 2025, 4:05 PM EDT - 1 year ago

Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025

Apr 23, 2025, 7:00 AM EDT - 1 year ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting

Apr 10, 2025, 9:30 AM EDT - 1 year ago

Pulse Biosciences Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Pulse Biosciences Earnings Call Transcript: Q4 2024

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference

Mar 7, 2025, 8:00 AM EST - 1 year ago

Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025

Mar 5, 2025, 10:30 AM EST - 1 year ago

Pulse Biosciences Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 20, 2025, 4:05 PM EST - 1 year ago

Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference

Feb 4, 2025, 8:00 AM EST - 1 year ago

Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

Jan 30, 2025, 8:00 AM EST - 1 year ago

Pulse Biosciences' Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting

Jan 21, 2025, 7:00 AM EST - 1 year ago

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium

LeisureSuitLarry May. 13 at 2:38 AM

$PLSE

0 · Reply

topstockalerts May. 12 at 9:31 PM

$PLSE wait… when did this get so strong?

0 · Reply

zzzdoc01 May. 12 at 8:10 PM

$PLSE obviously the market could care less what you think🤡🤣

0 · Reply

TruthBroker2 May. 12 at 7:27 PM

$PLSE Haters make us Greater. 🤣

0 · Reply

Orbit100 May. 12 at 7:26 PM

1 · Reply

Orbit100 May. 12 at 7:23 PM

$PLSE While Medtronic, Boston Scientific, Abbott and Johnson Johnson has fallen so far this year, it now makes PLSE over valued as a sell.

0 · Reply

Realtrader77 May. 12 at 6:56 PM

$PLSE buyout soon.

0 · Reply

Orbit100 May. 12 at 5:53 PM

$PLSE CFRA Reiterated since 05/09/2026 Sell CFRA Quantitative Report Latest Report 05/09/2026 Argus No rating provided by Argus Market Edge Reiterated since 05/04/2026 Avoid

0 · Reply

TruthBroker2 May. 12 at 5:32 PM

$SMMT $PLSE They Know.

0 · Reply

TruthBroker2 May. 12 at 2:42 PM

$PLSE Team Pulse

0 · Reply

notreload_ai May. 12 at 1:51 PM

$PLSE stock jumped after top executives bought $13M in shares, signaling strong confidence in future growth. https://notreload.xyz/xy/insider-buying-sends-pulse-biosciences-stock-higher/

0 · Reply

BIOTECH_GURU May. 12 at 1:51 PM

$PLSE insiders buying. I wonder why?! $100 within 12 months.

1 · Reply

LeisureSuitLarry May. 12 at 1:27 PM

$PLSE

0 · Reply

Sunugal780 May. 12 at 12:59 PM

$PLSE I opened a position here! GLA

0 · Reply

CEOBuysDisclosures May. 12 at 2:55 AM

$PLSE CEO purchased 15,000 shares at $19.69 for a total of $295,350. LAVIOLETTE PAUL A now owns 15,846 shares. https://ceo-buys.com

0 · Reply

CEOBuysDisclosures May. 12 at 12:55 AM

$PLSE CEO purchased 15,000 shares at $19.69 for a total of $295,350. LAVIOLETTE PAUL A now owns 15,000 shares. https://ceo-buys.com

0 · Reply

FilingTracker May. 11 at 10:53 PM

$PLSE Large insider purchase via ATM: https://www.sec.gov/Archives/edgar/data/1625101/000143774926016188/0001437749-26-016188-index.htm

0 · Reply

MarketBeat May. 8 at 8:07 PM

Pulse Biosciences Q1 Earnings Call Highlights $PLSE #PulseBiosciences #instantalerts #NASDAQ:PLSE https://www.marketbeat.com/instant-alerts

0 · Reply

buzzybob May. 8 at 11:55 AM

$PLSE Since there have been a few hints at a partnership announcement, wouldn't this be a good time for one? https://www.businesswire.com/news/home/20260508321314/en/Pulse-Biosciences-to-Present-at-the-BofA-Securities-2026-Healthcare-Conference Scheduled to present on Wednesday, May 13, at 4:35 pm PT.

0 · Reply

TruthBroker2 May. 7 at 10:32 PM

$SMMT $PLSE

0 · Reply

bob2013 May. 7 at 8:54 PM

$PLSE several partnerships in the works announcement coming soon.. Time appropriate.. Everyone wants in on this technology!!

1 · Reply

TruthBroker2 May. 6 at 10:46 PM

$PLSE

0 · Reply

Market Cap	1.30B
Revenue (ttm)	350,000.00
Net Income (ttm)	-72.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-20,794.29%
Debt to Equity Ratio	0.00

Volume	517,300
Avg Vol	276,932
Day's Range	N/A - N/A
Shares Out	68.23M
Stochastic %K	97%
Beta	1.63
Analysts	Strong Sell
Price Target	$30.00